Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Definitions

• Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries.
• These molecules collectively termed 'fine chemicals', include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes.
• Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules.
• One particularly useful organism for this purpose is Corynebacterium glutamicum, a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.
• the invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in C. glutamicum or related bacteria, the typing or identification of C. glutamicum or related bacteria, as reference points for mapping the C. glutamicum genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as membrane construction and membrane transport (MCT) proteins.
• MCT membrane construction and membrane transport
• C. glutamicum is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids.
• the MCT nucleic acid molecules of the invention therefore, can be used to identify microorganisms which can be used to produce fine chemicals, e.g., by fermentation processes.
• Modulation of the expression of the MCT nucleic acids of the invention, or modification of the sequence of the MCT nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism (e.g., to improve the yield or production of one or more fine chemicals from a Corynebacterium or Brevibacterium species).
• the MCT nucleic acids of the invention may also be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof, or to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms.
• the invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present.
• Corynebacterium glutamicum itself is nonpathogenic, it is related to species pathogenic in humans, such as Corynebacterium diphtheriae (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance.
• the MCT nucleic acid molecules of the invention may also serve as reference points for mapping of the C. glutamicum genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered Corynebacterium or Brevibacterium species.
• the MCT proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function involved in the metabolism (e.g., the biosynthesis or degradation) of compounds necessary for membrane biosynthesis, or of assisting in the transmembrane transport of one or more compounds either into or out of the cell.
• a function involved in the metabolism e.g., the biosynthesis or degradation
• the MCT proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function involved in the metabolism (e.g., the biosynthesis or degradation) of compounds necessary for membrane biosynthesis, or of assisting in the transmembrane transport of one or more compounds either into or out of the cell.
• the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals.
• This improved production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.
• an MCT protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a C. glutamicum strain incorporating such an altered protein.
• Those MCT proteins involved in the export of fine chemical molecules from the cell may be increased in number or activity such that greater quantities of these compounds are secreted to the extracellular medium, from which they are more readily recovered.
• those MCT proteins involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals e.g., phosphate, sulfate, nitrogen compounds, etc.
• these precursors, cofactors, or intermediate compounds are increased in concentration within the cell.
• fatty acids and lipids themselves are desirable fine chemicals; by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from C. glutamicum.
• MCT proteins of the invention involved in the export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the overproduction of the desired fine chemical) are efficiently exported before they are able to damage nucleotides and proteins within the cell (which would decrease the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the yield, production, or efficiency of production of the desired fine chemical).
• the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell, so by increasing the activity or number of transporters able to export this compound from the cell, one may increase the viability of the cell in culture, in turn leading to a greater number of cells in the culture producing the desired fine chemical.
• the MCT proteins of the invention may also be manipulated such that the relative amounts of different lipid and fatty acid molecules are produced. This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, as well as the integrity of the cell, both of which have a profound effect on the production of fine chemicals from C. glutamicum in large-scale fermentative culture.
• the invention provides novel nucleic acid molecules which encode proteins, referred to herein as MCT proteins, which are capable of, for example, participating in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• MCT proteins proteins
• Nucleic acid molecules encoding an MCT protein are referred to herein as MCT nucleic acid molecules.
• the MCT protein participates in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes. Examples of such proteins include those encoded by the genes set forth in Table 1.
• one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an MCT protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of MCT- encoding nucleic acid (e.g., DNA or mRNA).
• isolated nucleic acid molecules e.g., cDNAs, DNAs, or RNAs
• nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of MCT- encoding nucleic acid (e.g., DNA or mRNA).
• the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), forth as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or the coding region or a complement thereof of one of these nucleotide sequences.
• the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%), 99% or more homologous to a nucleotide sequence set forth as an odd-numbered SEQ ID NO in the Sequence Listing (e.g. , SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or a portion thereof.
• the isolated nucleic acid molecule encodes one of the amino acid sequences set forth as an even-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8).
• the preferred MCT proteins of the present invention also preferably possess at least one of the MCT activities described herein.
• the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence having an even-numbered SEQ ID NO: in the Sequence Listing), e.g., sufficiently homologous to an amino acid sequence of the invention such that the protein or portion thereof maintains an MCT activity.
• the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%) and most preferably at least about 95%>, 96%, 97%, 98%), or 99% or more homologous to an amino acid sequence of the invention (e.g., an entire amino acid sequence selected from those having an even-numbered SEQ ID NO in the Sequence Listing).
• the protein is a full length C.
• the isolated nucleic acid molecule is derived from C.
• glutamicum encodes a protein (e.g., an MCT fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered SEQ ID NOs in the Sequence Listing) and is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1 , and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.
• a protein e.g., an MCT fusion protein
• a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered SEQ ID NOs in the Sequence Listing) and is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in
• the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of the invention (e.g., a sequence of an odd- numbered SEQ ID NO in the Sequence Listing).
• the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring C. glutamicum MCT protein, or a biologically active portion thereof.
• vectors e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced.
• a host cell is used to produce an MCT protein by culturing the host cell in a suitable medium. The MCT protein can be then isolated from the medium or the host cell.
• Yet another aspect of the invention pertains to a genetically altered microorganism in which an MCT gene has been introduced or altered.
• the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated MCT sequence as a transgene.
• an endogenous MCT gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered MCT gene.
• an endogenous or introduced MCT gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MCT protein.
• one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an MCT gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the MCT gene is modulated.
• the microorganism belongs to the genus Corynebacterium or Brevibacterium, with Corynebacterium glutamicum being particularly preferred.
• the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.
• the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject.
• This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in the Sequence Listing as SEQ ID NOs 1 through 676) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject.
• Still another aspect of the invention pertains to an isolated MCT protein or a portion, e.g., a biologically active portion, thereof.
• the isolated MCT protein or portion thereof can participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• the isolated MCT protein or portion thereof is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: in the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• the invention also provides an isolated preparation of an MCT protein.
• the MCT protein comprises an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing).
• the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) (encoded by an open reading frame set forth in a corresponding odd-numbered SEQ ID NO: of the Sequence Listing A).
• the protein is at least about 50%), preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%>, 96%, 97%, 98%, or 99%> or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing).
• the isolated MCT protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1.
• the isolated MCT protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g. , hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%), more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%>, 97%), 98,%>, or 99% or more homologous, to a nucleotide sequence of one of the even-numbered SEQ ID NOs set forth in the Sequence Listing. It is also preferred that the preferred forms of MCT proteins also have one or more of the MCT bioactivities described herein.
• the MCT polypeptide, or a biologically active portion thereof, can be operatively linked to a non-MCT polypeptide to form a fusion protein.
• this fusion protein has an activity which differs from that of the MCT protein alone.
• this fusion protein participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• integration of this fusion protein into a host cell modulates production of a desired compound from the cell.
• the invention provides methods for screening molecules which modulate the activity of an MCT protein, either by interacting with the protein itself or a substrate or binding partner of the MCT protein, or by modulating the transcription or translation of an MCT nucleic acid molecule of the invention.
• Another aspect of the invention pertains to a method for producing a fine chemical.
• This method involves the culturing of a cell containing a vector directing the expression of an MCT nucleic acid molecule of the invention, such that a fine chemical is produced.
• this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of an MCT nucleic acid.
• this method further includes the step of recovering the fine chemical from the culture.
• the cell is from the genus Corynebacterium or Brevibacterium, or is selected from those strains set forth in Table 3.
• Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism.
• Such methods include contacting the cell with an agent which modulates MCT protein activity or MCT nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent.
• the cell is modulated for one or more C. glutamicum metabolic pathways for cell membrane components or is modulated for the transport of compounds across such membranes, such that the yields or rate of production of a desired fine chemical by this microorganism is improved.
• the agent which modulates MCT protein activity can be an agent which stimulates MCT protein activity or MCT nucleic acid expression.
• agents which stimulate MCT protein activity or MCT nucleic acid expression include small molecules, active MCT proteins, and nucleic acids encoding MCT proteins that have been introduced into the cell.
• agents which inhibit MCT activity or expression include small molecules and antisense MCT nucleic acid molecules.
• Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant MCT gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased.
• said chemical is a fine chemical.
• said fine chemical is an amino acid.
• said amino acid is L-lysine.
• the present invention provides MCT nucleic acid and protein molecules which are involved in the metabolism of cellular membrane components in C. glutamicum or in the transport of compounds across such membranes.
• the molecules of the invention may be utilized in the modulation of production of fine chemicals from microorganisms, such as C. glutamicum, either directly (e.g., where overexpression or optimization of a fatty acid biosynthesis protein has a direct impact on the yield, production, and/or efficiency of production of the fatty acid from modified C.
• glutamicum may have an indirect impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound (e.g., where modulation of the metabolism of cell membrane components results in alterations in the yield, production, and/or efficiency of production or the composition of the cell membrane, which in turn may impact the production of one or more fine chemicals).
• modulation of the metabolism of cell membrane components results in alterations in the yield, production, and/or efficiency of production or the composition of the cell membrane, which in turn may impact the production of one or more fine chemicals.
• the term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries.
• Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al, eds.
• VCH Weinheim, and references contained therein
• lipids both saturated and unsaturated fatty acids (e.g., arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g., hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L.
• Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms.
• amino acid is art- recognized.
• the proteinogenic amino acids of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)).
• Amino acids may be in the D- or L- optical configuration, though L- amino acids are generally the only type found in naturally-occurring proteins.
• the 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 1 1 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.
• Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine.
• Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L- methionine and tryptophan are all utilized in the pharmaceutical industry.
• Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L- methionine are common feed additives. (Leuchtenberger, W. (1996) Amino aids - technical production and use, p. 466-502 in Rehm et al. (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim).
• amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N- acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.
• cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain ⁇ -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase.
• Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11- step pathway.
• Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase.
• Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis.
• Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle.
• Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate.
• Isoleucine is formed from threonine.
• a complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-l-pyrophosphate, an activated sugar.
• Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3 rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle” p. 495-516 (1988)).
• the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them.
• amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L.
• Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman' s Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p.
• vitamin is art- recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself.
• the group of vitamins may encompass cofactors and nutraceutical compounds.
• cofactor includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic.
• nutraceutical includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).
• Thiamin (vitamin Bi) is produced by the chemical coupling of pyrimidine and thiazole moieties.
• Riboflavin (vitamin B 2 ) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5 '-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).
• 'vitamin B 6 ' e.g., pyridoxine, pyridoxamine, pyridoxa- 5 '-phosphate, and the commercially used pyridoxin hydrochloride
• Pantothenate pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-l-oxobutyl)- ⁇ -alanine
• pantothenate biosynthesis consist of the ATP-driven condensation of ⁇ -alanine and pantoic acid.
• pantothenate The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to ⁇ - alanine and for the condensation to panthotenic acid are known.
• the metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps.
• Pantothenate, pyridoxal-5' -phosphate, cysteine and ATP are the precursors of Coenzyme A.
• These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)- panthenol (provitamin B 5 ), pantetheine (and its derivatives) and coenzyme A.
• Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins.
• Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the ⁇ -ketoglutarate dehydrogenase complex.
• the folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6- methylpterin.
• guanosine-5'-triphosphate GTP
• L-glutamic acid L-glutamic acid
• p- amino-benzoic acid has been studied in detail in certain microorganisms.
• Corrinoids such as the cobalamines and particularly vitamin B J2
• po ⁇ hyrines belong to a group of chemicals characterized by a tetrapyrole ring system.
• the biosynthesis of vitamin B 1 is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known.
• Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'.
• Niacin is the precursor of the important coenzymes NAD
• purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections.
• the language “purine” or “pyrimidine” includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides.
• the term “nucleotide” includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid.
• the language “nucleoside” includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess.
• nucleic acid molecules By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).
• energy stores i.e., AMP
• coenzymes i.e., FAD and NAD
• purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and Related Compounds in Biotechnology vol. 6, Rehm et al, eds. VCH: Weinheim, p. 561- 612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.
• fine chemicals e.g., thiamine, S-adenosyl-me
• Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'- phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5 '-triphosphate (CTP).
• IMP inosine-5'- phosphate
• AMP adenosine-5'-monophosphate
• deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.
• Trehalose consists of two glucose molecules, bound in ⁇ , ⁇ -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto et al, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) Trends Biotech. 16: 460- 467; Paiva, C.L.A. and Panek, A.D. (1996) Biotech. Ann. Rev. 2: 293-314; and Shiosaka, M. (1997) J. Japan 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.
• Cellular membranes serve a variety of functions in a cell. First and foremost, a membrane differentiates the contents of a cell from the surrounding environment, thus giving integrity to the cell. Membranes may also serve as barriers to the influx of hazardous or unwanted compounds, and also to the efflux of desired compounds. Cellular membranes are by nature impervious to the unfacilitated diffusion of hydrophilic compounds such as proteins, water molecules and ions due to their structure: a bilayer of lipid molecules in which the polar head groups face outwards (towards the exterior and interior of the cell, respectively) and the nonpolar tails face inwards at the center of the bilayer, forming a hydrophobic core (for a general review of membrane structure and function, see Gennis, R.B.
• This regulation, or 'gating' is generally specific to the molecules to be transported by the pore or channel, rendering these transmembrane constructs selectively permeable to a specific class of substrates; for example, a potassium channel is constructed such that only ions having a like charge and size to that of potassium may pass through.
• Channel and pore proteins tend to have discrete hydrophobic and hydrophilic domains, such that the hydrophobic face of the protein may associate with the interior of the membrane while the hydrophilic face lines the interior of the channel, thus providing a sheltered hydrophilic environment through which the selected hydrophilic molecule may pass.
• Many such pores/channels are known in the art, including those for potassium, calcium, sodium, and chloride ions.
• This pore and channel-mediated system of facilitated diffusion is limited to very small molecules, such as ions, because pores or channels large enough to permit the passage of whole proteins by facilitated diffusion would be unable to prevent the passage of smaller hydrophilic molecules as well. Transport of molecules by this process is sometimes termed 'facilitated diffusion' since the driving force of a concentration gradient is required for the transport to occur. Permeases also permit facilitated diffusion of larger molecules, such as glucose or other sugars, into the cell when the concentration of these molecules on one side of the membrane is greater than that on the other (also called 'uniport').
• these integral membrane proteins do not form open channels through the membrane, but rather bind to the target molecule at the surface of the membrane and then undergo a conformational shift such that the target molecule is released on the opposite side of the membrane.
• symport or antiport couples the movement of two different molecules across the membrane (via permeases having two separate binding sites for the two different molecules); in symport, both molecules are transported in the same direction, while in antiport, one molecule is imported while the other is exported. This is possible energetically because one of the two molecules moves in accordance with a concentration gradient, and this energetically favorable event is permitted only upon concomitant movement of a desired compound against the prevailing concentration gradient.
• Single molecules may be transported across the membrane against the concentration gradient in an energy-driven process, such as that utilized by the ABC transporters.
• the transport protein located in the membrane has an ATP-binding cassette; upon binding of the target molecule, the ATP is converted to ADP + Pi, and the resulting release of energy is used to drive the movement of the target molecule to the opposite face of the membrane, facilitated by the transporter.
• the transport protein located in the membrane has an ATP-binding cassette; upon binding of the target molecule, the ATP is converted to ADP + Pi, and the resulting release of energy is used to drive the movement of the target molecule to the opposite face of the membrane, facilitated by the transporter.
• lipid molecules The synthesis of membranes is a well-characterized process involving a number of components, the most important of which are lipid molecules. Lipid synthesis may be divided into two parts: the synthesis of fatty acids and their attachment to sn- glycerol-3 -phosphate, and the addition or modification of a polar head group. Typical lipids utilized in bacterial membranes include phospholipids, glycolipids, sphingolipids, and phosphoglycerides. Fatty acid synthesis begins with the conversion of acetyl CoA either to malonyl CoA by acetyl CoA carboxylase, or to acetyl-ACP by acetyltransacylase.
• CFA cyclopropane fatty acids
• lipid synthesis Another essential step in lipid synthesis is the transfer of fatty acids onto the polar head groups by, for example, glycerol-phosphate-acyltransferases.
• the combination of various precursor molecules and biosynthetic enzymes results in the production of different fatty acid molecules, which has a profound effect on the composition of the membrane.
• the present invention is based, at least in part, on the discovery of novel molecules, referred to herein as MCT nucleic acid and protein molecules, which control the production of cellular membranes in C. glutamicum and govern the movement of molecules across such membranes.
• MCT molecules participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• the activity of the MCT molecules of the present invention to regulate membrane component production and membrane transport has an impact on the production of a desired fine chemical by this organism.
• the MCT molecules of the invention are modulated in activity, such that the C.
• glutamicum metabolic pathways which the MCT proteins of the invention regulate are modulated in yield, production, and/or efficiency of production and the transport of compounds through the membranes is altered in efficiency, which either directly or indirectly modulates the yield, production, and/or efficiency of production of a desired fine chemical by C. glutamicum.
• MCT protein or “MCT polypeptide” includes proteins which participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• MCT proteins include those encoded by the MCT genes set forth in Table 1 and by the odd-numbered SEQ ID NOs.
• MCT gene or “MCT nucleic acid sequence” include nucleic acid sequences encoding an MCT protein, which consist of a coding region and also corresponding untranslated 5' and 3' sequence regions.
• MCT genes include those set forth in Table 1.
• production or “productivity” are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter).
• efficiency of production includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical).
• yield or “product/carbon yield” is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source.
• biosynthetic pathway are art-recognized and include, the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process.
• degradation or a “degradation pathway” are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process.
• the language “metabolism” is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound.
• the MCT molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as C. glutamicum.
• a desired molecule such as a fine chemical
• C. glutamicum a microorganism
• MCT proteins involved in the export of fine chemical molecules from the cell may be increased in number or activity such that greater quantities of these compounds are secreted to the extracellular medium, from which they are more readily recovered.
• those MCT proteins involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals may be increased in number or activity such that these precursor , cofactor, or intermediate compounds are increased in concentration within the cell.
• fatty acids and lipids themselves are desirable fine chemicals; by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from C. glutamicum.
• MCT proteins of the invention involved in the export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the ove ⁇ roduction of the desired fine chemical) are efficiently exported before they are able to damage nucleotides and proteins within the cell (which would decrease the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the yield, production, or efficiency of production of the desired fine chemical).
• the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell, so by increasing the activity or number of transporters able to export this compound from the cell, one may increase the viability of the cell in culture, in turn leading to a greater number of cells in the culture producing the desired fine chemical.
• the MCT proteins of the invention may also be manipulated such that the relative amounts of different lipid and fatty acid molecules are produced. This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, as well as the integrity of the cell, both of which have a profound effect on the production of fine chemicals from C. glutamicum in large-scale fermentative culture.
• the isolated nucleic acid sequences of the invention are contained within the genome of a Corynebacterium glutamicum strain available through the American Type Culture Collection, given designation ATCC 13032.
• the nucleotide sequence of the isolated C. glutamicum MCT DNAs and the predicted amino acid sequences of the C. glutamicum MCT proteins are shown in the Sequence Listing as odd-numbered SEQ ID NOs and even-numbered SEQ ID NOs, respectively. Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode proteins involved in the metabolism of cellular membrane components or proteins involved in the transport of compounds across such membranes.
• the present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of the invention (e.g., the sequence of an even-numbered SEQ ID NO of the Sequence Listing).
• a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g. , the entire selected amino acid sequence.
• a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%), 80-90%, or 90-95%, and most preferably at least about 96%), 97%), 98%, 99%> or more homologous to the selected amino acid sequence.
• the MCT protein or a biologically active portion or fragment thereof of the invention can participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or have one or more of the activities set forth in Table 1.
• Various aspects of the invention are described in further detail in the following subsections:
• nucleic acid molecules that encode MCT polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of MCT-encoding nucleic acid (e.g., MCT DNA).
• nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
• nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
• isolated nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid.
• an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
• the isolated MCT nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g, a C. glutamicum cell).
• an "isolated" nucleic acid molecule such as a DNA molecule
• a nucleic acid molecule of the present invention e.g., a nucleic acid molecule having a nucleotide sequence of an odd-numbered SEQ ID NO of the Sequence Listing, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a C. glutamicum MCT DNA can be isolated from a C.
• glutamicum library using all or portion of one of the odd-numbered SEQ ID NO sequences of the Sequence Listing as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T ' . Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
• nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered SEQ ID NO of the Sequence Listing) can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence).
• mRNA can be isolated from normal endothelial cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (1979) Biochemistry 18: 5294-5299) and DNA can be prepared using reverse transcriptase (e.g. , Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL).
• reverse transcriptase e.g. , Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL.
• Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in the Sequence Listing.
• a nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
• the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
• oligonucleotides corresponding to an MCT nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
• an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in the Sequence Listing.
• the nucleic acid sequences of the invention, as set forth in the Sequence Listing correspond to the Corynebacterium glutamicum MCT DNAs of the invention.
• This DNA comprises sequences encoding MCT proteins (i.e., the "coding region", indicated in each odd- numbered SEQ ID NO: in the Sequence Listing), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in each odd-numbered SEQ ID NO: in the Sequence Listing.
• the nucleic acid molecule can comprise only the coding region of any of the nucleic acid sequences of the Sequence Listing.
• each of the nucleic acid and amino acid sequences set forth in the Sequence Listing has an identifying RXA, RXN, RXS, or RXC number having the designation "RXA”, “RXN”, “RXS” or “RXC” followed by 5 digits (i.e., RXA02099, RXN03097, RXS00148, or RXC01748).
• Each of the nucleic acid sequences comprises up to three parts: a 5' upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same RXA, RXN, RXS, or RXC designation to eliminate confusion.
• the coding region of each of these sequences is translated into a corresponding amino acid sequence, which is also set forth in the Sequence Listing, as an even-numbered SEQ ID NO: immediately following the corresponding nucleic acid sequence.
• the coding region for RXA03097 is set forth in SEQ ID NO: 1
• the amino acid sequence which it encodes is set forth as SEQ ID NO:2.
• sequences of the nucleic acid molecules of the invention are identified by the same RXA, RXN, RXS, or RXC designations as the amino acid molecules which they encode, such that they can be readily correlated.
• amino acid sequences designated RXA02099, RXN03097, RXS00148, and RXC01748 are translations of the coding region of the nucleotide sequences of nucleic acid molecules RXA02099, RXN03097, RXS00148, and RXC01748, respectively.
• the correspondence between the RXA, RXN, RXS, and RXC nucleotide and amino acid sequences of the invention and their assigned SEQ ID NOs is set forth in Table 1.
• the nucleotide sequence of RXA00104 is SEQ ID NO:5
• amino acid sequence of RXA00104 is SEQ ID NO:6.
• F-designated genes include those genes set forth in Table 1 which have an 'F' in front of the RXA, RXN, RXS, or RXC designation.
• SEQ ID NO: 11 designated, as indicated on Table 1, as "F RXA02581”
• SEQ ID NOs: 31, 33, and 43 are SEQ ID NOs: 31, 33, and 43 (designated on Table 1 as "F RXA02487”, “F RXA02490", and "F RXA02809", respectively).
• the nucleic acid molecules of the present invention are not intended to include those compiled in Table 2.
• a sequence for this gene was published in Wehrmann, A., et al. (1998) J. Bacteriol. 180(12): 3159- 3165.
• the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.
• an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof.
• a nucleic acid molecule which is complementary to one of the nucleotide sequences shown in of the invention is one which is sufficiently complementary to one of the nucleotide sequences shown in the Sequence Listing (e.g., the sequence of an odd-numbered SEQ ID NO:)such that it can hybridize to one of the nucleotide sequences of the invention, thereby forming a stable duplex.
• an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%), 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%), 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof.
• an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences of the invention, or a portion thereof.
• the nucleic acid molecule of the invention can comprise only a portion of the coding region of the sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an MCT protein.
• the nucleotide sequences determined from the cloning of the MCT genes from C. glutamicum allows for the generation of probes and primers designed for use in identifying and/or cloning MCT homologues in other cell types and organisms, as well as MCT homologues from other Corynebacteria or related species.
• the probe/primer typically comprises substantially purified oligonucleotide.
• the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the nucleotide sequences of the invention (e.g., a sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing), an anti-sense sequence of one of these sequences, or naturally occurring mutants thereof.
• Primers based on a nucleotide sequence of the invention can be used in PCR reactions to clone MCT homologues. Probes based on the MCT nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins.
• the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
• the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
• Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an MCT protein, such as by measuring a level of an MCT-encoding nucleic acid in a sample of cells, e.g., detecting MCT mRNA levels or determining whether a genomic MCT gene has been mutated or deleted.
• the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even- numbered SEQ ID NO of the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes.
• the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in a sequence of one of the even-numbered SEQ ID NOs of the Sequence Listing) amino acid residues to an amino acid sequence of the invention such that the protein or portion thereof is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes. Protein members of such membrane component metabolic pathways or membrane transport systems, as described herein, may play a role in the production and secretion of one or more fine chemicals. Examples of such activities are also described herein.
• the function of an MCT protein contributes either directly or indirectly to the yield, production, and/or efficiency of production of one or more fine chemicals.
• MCT protein activities are set forth in Table 1.
• the protein is at least about 50-60%), preferably at least about 60-70%), and more preferably at least about 70-80%), 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%>, 99% or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing).
• portions of proteins encoded by the MCT nucleic acid molecules of the invention are preferably biologically active portions of one of the MCT proteins.
• biologically active portion of an MCT protein is intended to include a portion, e.g., a domain/motif, of an MCT protein that participates in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or has an activity as set forth in Table 1.
• an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification. Additional nucleic acid fragments encoding biologically active portions of an MCT protein.
• MCT protein can be prepared by isolating a portion of one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing), expressing the encoded portion of the MCT protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the MCT protein or peptide.
• a portion of one of the amino acid sequences of the invention e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing
• expressing the encoded portion of the MCT protein or peptide e.g., by recombinant expression in vitro
• the invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing) (and portions thereof) due to degeneracy of the genetic code and thus encode the same MCT protein as that encoded by the nucleotide sequences of the invention.
• an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in the Sequence Listing (e.g., an even-numbered SEQ ID NO:).
• the nucleic acid molecule of the invention encodes a full length C.
• glutamicum protein which is substantially homologous to an amino acid sequence of the invention (encoded by an open reading frame shown in an odd-numbered SEQ ID NO: of the Sequence Listing). It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention.
• the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g., a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4).
• the invention includes a nucleotide sequence which is greater than and/or at least 38%o identical to the nucleotide sequence designated RXA01420 (SEQ ID NO: 7), a nucleotide sequence which is greater than and/or at least 43% identical to the nucleotide sequence designated RXA00104 (SEQ ID NO:5), and a nucleotide sequence which is greater than and/or at least 45% identical to the nucleotide sequence designated RXA02173 (SEQ ID NO:25).
• nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated are also encompassed by the invention.
• DNA sequence polymo ⁇ hisms that lead to changes in the amino acid sequences of MCT proteins may exist within a population (e.g. , the C. glutamicum population).
• Such genetic polymo ⁇ hism in the MCT gene may exist among individuals within a population due to natural variation.
• the terms "gene” and "recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding an MCT protein, preferably a C. glutamicum MCT protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the MCT gene.
• nucleic acid molecules corresponding to natural variants and non- glutamicum homologues of the C. glutamicum MCT DNA of the invention can be isolated based on their homology to the C. glutamicum MCT nucleic acid disclosed herein using the C. glutamicum DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
• an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of an odd-numbered SEQ ID NO: of the Sequence Listing.
• the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length.
• hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
• the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other.
• stringent conditions are known to those of ordinary skill in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
• a preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.
• an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a nucleotide sequence of the invention corresponds to a naturally-occurring nucleic acid molecule.
• a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g. , encodes a natural protein).
• the nucleic acid encodes a natural C. glutamicum MCT protein.
• a "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the MCT proteins (e.g., an even-numbered SEQ ID NO: of the Sequence Listing) without altering the activity of said MCT protein, whereas an "essential" amino acid residue is required for MCT protein activity.
• Other amino acid residues e.g., those that are not conserved or only semi-conserved in the domain having MCT activity
• another aspect of the invention pertains to nucleic acid molecules encoding MCT proteins that contain changes in amino acid residues that are not essential for MCT activity.
• the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of the invention and is capable of participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or has one or more activities set forth in Table 1.
• the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to the amino acid sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing , more preferably at least about 60-70% homologous to one of these sequences, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of these sequences, and most preferably at least about 96%, 97%, 98%, or 99%) homologous to one of the amino acid sequences of the invention..
• the sequences are aligned for optimal comparison pu ⁇ oses (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid).
• the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
• amino acid or nucleic acid "homology” is equivalent to amino acid or nucleic acid "identity”
• An isolated nucleic acid molecule encoding an MCT protein homologous to a protein sequence of the invention can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of the invention such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the nucleotide sequences of the invention by standard techniques, such as site-directed mutagenesis and PCR- mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
• a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
• Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
• a predicted nonessential amino acid residue in an MCT protein is preferably replaced with another amino acid residue from the same side chain family.
• mutations can be introduced randomly along all or part of an MCT coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an MCT activity described herein to identify mutants that retain MCT activity.
• the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification).
• an antisense nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
• the antisense nucleic acid can be complementary to an entire MCT coding strand, or to only a portion thereof.
• an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an MCT protein.
• coding region refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g. , the entire coding region of SEQ ID NO: 5 (RXA00104) comprises nucleotides 1 to 756).
• the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding MCT.
• noncoding region refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids ( . e. , also referred to as 5' and 3' untranslated regions).
• antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing.
• the antisense nucleic acid molecule can be complementary to the entire coding region of MCT mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of MCT mRNA.
• the antisense oligonucleotide can be complementary to the region surrounding the translation start site of MCT mRNA.
• An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
• An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
• an antisense nucleic acid e.g., an antisense oligonucleotide
• an antisense nucleic acid e.g., an antisense oligonucleotide
• modified nucleotides which can be used to generate the antisense nucleic acid include 5- fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4- acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2- thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1 -methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5- methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5- methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,
• the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
• the antisense nucleic acid molecules of the invention are typically administered to a cell or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an MCT protein to thereby inhibit expression of the protein, e.g. , by inhibiting transcription and/or translation.
• the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
• the antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen.
• the antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.
• the antisense nucleic acid molecule of the invention is an ⁇ -anomeric nucleic acid molecule.
• An ⁇ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641).
• the antisense nucleic acid molecule can also comprise a 2'-o- methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
• an antisense nucleic acid of the invention is a ribozyme.
• Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
• ribozymes e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave MCT mRNA transcripts to thereby inhibit translation of MCT mRNA.
• a ribozyme having specificity for an MCT-encoding nucleic acid can be designed based upon the nucleotide sequence of an MCT DNA disclosed herein (i.e., SEQ ID NO. 5 (RXA00104).
• SEQ ID NO. 5 RXA00104
• a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an MCT-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071 and Cech et al. U.S. Patent No. 5,116,742.
• MCT mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261 :1411-1418.
• MCT gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an MCT nucleotide sequence (e.g., an MCT promoter and/or enhancers) to form triple helical structures that prevent transcription of an MCT gene in target cells.
• an MCT nucleotide sequence e.g., an MCT promoter and/or enhancers
• vectors preferably expression vectors, containing a nucleic acid encoding an MCT protein (or a portion thereof).
• vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
• plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
• viral vector Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome.
• Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
• vectors e.g., non-episomal mammalian vectors
• Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
• certain vectors are capable of directing the expression of genes to which they are operatively linked.
• Such vectors are referred to herein as "expression vectors".
• expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
• plasmid and vector can be used interchangeably as the plasmid is the most commonly used form of vector.
• the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g. , replication defective retroviruses, adenoviruses and adeno- associated viruses), which serve equivalent functions.
• the recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed.
• "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
• regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells.
• Preferred regulatory sequences are, for example, promoters such as cos-, tac-, t ⁇ -, tet-, t ⁇ -tet-, lpp-, lac-, lpp-lac-, lacl q -, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, ⁇ -P R - or ⁇ P L , which are used preferably in bacteria.
• promoters such as cos-, tac-, t ⁇ -, tet-, t ⁇ -tet-, lpp-, lac-, lpp-lac-, lacl q -, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, ⁇ -P R - or ⁇ P L , which are used preferably in bacteria.
• Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC1, MF ⁇ , AC, P-60, CYC1, GAPDH, TEF, ⁇ 28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by one of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
• the expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., MCT proteins, mutant forms of MCT proteins, fusion proteins, etc.).
• the recombinant expression vectors of the invention can be designed for expression of MCT proteins in prokaryotic or eukaryotic cells.
• MCT genes can be expressed in bacterial cells such as C. glutamicum, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M. A. et al.
• Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins.
• Such fusion vectors typically serve three pu ⁇ oses: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
• a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
• enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
• Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase
• the coding sequence of the MCT protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein.
• the fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant MCT protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.
• Suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al, (1988) Gene 69:301-315) pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHSl, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN- III 113-B1, ⁇ gtl 1, pBdCl, and pET l id (Studier et al, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89 ; and Pouwels et al, eds.
• Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid t ⁇ -lac fusion promoter.
• Target gene expression from the pET l id vector relies on transcription from a T7 gnlO-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ⁇ prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected.
• the plasmids pIJlOl, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces, while plasmids pUB 110, pC 194, or pBD214 are suited for transformation of Bacillus species.
• plasmids pUB 110, pC 194, or pBD214 are suited for transformation of Bacillus species.
• plasmids of use in the transfer of genetic information into Corynebacterium include pHM1519, pBLl, pSA77, or pAJ667 (Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).
• One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 1 19-128).
• Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as C. glutamicum (Wada et ⁇ /. (1992) Nucleic Acids Res. 20:2111-2118).
• Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
• the MCT protein expression vector is a yeast expression vector.
• yeast expression vectors for expression in yeast S. cerevisiae include pYepSecl (Baldari, et al, (1987) Embo J. 6:229-234), 2 ⁇ , pAG-1, Yep6, Yepl3, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al, (1987) Gene 54:113-123), and pYES2 (Invitrogen Co ⁇ oration, San Diego, CA).
• Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, et al, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York (IBSN 0 444 904018).
• the MCT proteins of the invention can be expressed in insect cells using baculovirus expression vectors.
• Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
• the MCT proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g., the spermatophytes, such as crop plants).
• plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border", Plant Mol. Biol. 20: 1195-1197; and Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant transformation", Nucl Acid. Res.
• a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector.
• mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195).
• the expression vector's control functions are often provided by viral regulatory elements.
• commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
• suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
• the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
• tissue-specific regulatory elements are known in the art.
• suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1 :268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J.
• promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the ⁇ -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
• the invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to MCT mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
• the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
• a high efficiency regulatory region the activity of which can be determined by the cell type into which the vector is introduced.
• host cell and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
• a host cell can be any prokaryotic or eukaryotic cell.
• an MCT protein can be expressed in bacterial cells such as C.
• mice Suitable host cells are known to one of ordinary skill in the art.
• Microorganisms related to Corynebacterium glutamicum which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.
• Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
• transformation and “transfection”, “conjugation” and “transduction” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-mediated transfer, or electroporation.
• foreign nucleic acid e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.
• Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
• a gene that encodes a selectable marker e.g., resistance to antibiotics
• Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
• Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an MCT protein or can be introduced on a separate vector.
• Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have inco ⁇ orated the selectable marker gene will survive, while the other cells die).
• a vector which contains at least a portion of an MCT gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the MCT gene.
• this MCT gene is a Corynebacterium glutamicum MCT gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source.
• the vector is designed such that, upon homologous recombination, the endogenous MCT gene is functionally disrupted ( . e. , no longer encodes a functional protein; also referred to as a "knock out" vector).
• the vector can be designed such that, upon homologous recombination, the endogenous MCT gene is mutated or otherwise altered but still encodes functional protein (e.g. , the upstream regulatory region can be altered to thereby alter the expression of the endogenous MCT protein).
• the altered portion of the MCT gene is flanked at its 5' and 3' ends by additional nucleic acid of the MCT gene to allow for homologous recombination to occur between the exogenous MCT gene carried by the vector and an endogenous MCT gene in a microorganism.
• the additional flanking MCT nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
• flanking DNA both at the 5' and 3' ends
• flanking DNA both at the 5' and 3' ends
• the vector is introduced into a microorganism (e.g. , by electroporation) and cells in which the introduced MCT gene has homologously recombined with the endogenous MCT gene are selected, using art-known techniques.
• recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene.
• inclusion of an MCT gene on a vector placing it under control of the lac operon permits expression of the MCT gene only in the presence of IPTG.
• Such regulatory systems are well known in the art.
• an endogenous MCT gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur.
• an endogenous or introduced MCT gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MCT protein.
• one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an MCT gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the MCT gene is modulated.
• a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an MCT protein.
• the invention further provides methods for producing MCT proteins using the host cells of the invention.
• the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an MCT protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered MCT protein) in a suitable medium until MCT protein is produced.
• the method further comprises isolating MCT proteins from the medium or the host cell.
• Another aspect of the invention pertains to isolated MCT proteins, and biologically active portions thereof.
• An “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
• the language “substantially free of cellular material” includes preparations of MCT protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced.
• the language "substantially free of cellular material” includes preparations of MCT protein having less than about 30% (by dry weight) of non-MCT protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-MCT protein, still more preferably less than about 10% of non-MCT protein, and most preferably less than about 5% non-MCT protein.
• non-MCT protein also referred to herein as a "contaminating protein”
• the MCT protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%), more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.
• the language “substantially free of chemical precursors or other chemicals” includes preparations of MCT protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein.
• the language “substantially free of chemical precursors or other chemicals” includes preparations of MCT protein having less than about 30% (by dry weight) of chemical precursors or non-MCT chemicals, more preferably less than about 20% chemical precursors or non-MCT chemicals, still more preferably less than about 10%) chemical precursors or non-MCT chemicals, and most preferably less than about 5% chemical precursors or non-MCT chemicals.
• isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the MCT protein is derived.
• such proteins are produced by recombinant expression of, for example, a C. glutamicum MCT protein in a microorganism such as C. glutamicum.
• An isolated MCT protein or a portion thereof of the invention can participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1.
• the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) such that the protein or portion thereof maintains the ability participate in the metabolism of compounds necessary for the construction of cellular membranes in C.
• an MCT protein of the invention has an amino acid sequence set forth as an even-numbered SEQ ID NO: of the Sequence Listing.
• the MCT protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing).
• the MCT protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to one of the nucleic acid sequences of the invention, or a portion thereof.
• Ranges and identity values intermediate to the above-recited values, (e.g., 70-90%) identical or 80-95% identical) are also intended to be encompassed by the present invention.
• ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included.
• the preferred MCT proteins of the present invention also preferably possess at least one of the MCT activities described herein.
• a preferred MCT protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention, and which can participate in the metabolism of compounds necessary for the construction of cellular membranes in C. glutamicum, or in the transport of molecules across these membranes, or which has one or more of the activities set forth in Table 1.
• the MCT protein is substantially homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and retains the functional activity of the protein of one of the amino acid sequences of the invention yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above.
• the MCT protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99%> or more homologous to an entire amino acid sequence of the invention and which has at least one of the MCT activities described herein.
• Ranges and identity values intermediate to the above-recited values are also intended to be encompassed by the present invention.
• ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included.
• the invention pertains to a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of the invention.
• Biologically active portions of an MCT protein include peptides comprising amino acid sequences derived from the amino acid sequence of an MCT protein, e.g., the an amino acid sequence of an even-numbered SEQ ID NO: of the Sequence Listing or the amino acid sequence of a protein homologous to an MCT protein, which include fewer amino acids than a full length MCT protein or the full length protein which is homologous to an MCT protein, and exhibit at least one activity of an MCT protein.
• biologically active portions peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length
• biologically active portions in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein.
• the biologically active portions of an MCT protein include one or more selected domains/motifs or portions thereof having biological activity.
• MCT proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the MCT protein is expressed in the host cell. The MCT protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.
• an MCT protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques.
• native MCT protein can be isolated from cells (e.g., endothelial cells), for example using an anti-MCT antibody, which can be produced by standard techniques utilizing an MCT protein or fragment thereof of this invention.
• an MCT chimeric protein or “fusion protein” comprises an MCT polypeptide operatively linked to a non-MCT polypeptide.
• An “MCT polypeptide” refers to a polypeptide having an amino acid sequence corresponding to an MCT protein
• a non-MCT polypeptide refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the MCT protein, e.g., a protein which is different from the MCT protein and which is derived from the same or a different organism.
• the term "operatively linked" is intended to indicate that the MCT polypeptide and the non-MCT polypeptide are fused in-frame to each other.
• the non-MCT polypeptide can be fused to the N-terminus or C- terminus of the MCT polypeptide.
• the fusion protein is a GST-MCT fusion protein in which the MCT sequences are fused to the C-terminus of the GST sequences.
• Such fusion proteins can facilitate the purification of recombinant MCT proteins.
• the fusion protein is an MCT protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of an MCT protein can be increased through use of a heterologous signal sequence.
• an MCT chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques.
• DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
• the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
• PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992).
• many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
• An MCT- encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the MCT protein. Homologues of the MCT protein can be generated by mutagenesis, e.g.
• the term "homologue” refers to a variant form of the MCT protein which acts as an agonist or antagonist of the activity of the MCT protein.
• An agonist of the MCT protein can retain substantially the same, or a subset, of the biological activities of the MCT protein.
• An antagonist of the MCT protein can inhibit one or more of the activities of the naturally occurring form of the MCT protein, by, for example, competitively binding to a downstream or upstream member of the cell membrane component metabolic cascade which includes the MCT protein, or by binding to an MCT protein which mediates transport of compounds across such membranes, thereby preventing translocation from taking place.
• homologues of the MCT protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the MCT protein for MCT protein agonist or antagonist activity.
• a variegated library of MCT variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
• a variegated library of MCT variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential MCT sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of MCT sequences therein.
• a degenerate set of potential MCT sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of MCT sequences therein.
• fusion proteins e.g., for phage display
• degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential MCT sequences.
• Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3; Itakura et ⁇ /. (1984) Annu. Rev. Biochem. 53:323; Itakura et ⁇ /. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11 :477.
• libraries of fragments of the MCT protein coding can be used to generate a variegated population of MCT fragments for screening and subsequent selection of homologues of an MCT protein.
• a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an MCT coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with SI nuclease, and ligating the resulting fragment library into an expression vector.
• an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the MCT protein.
• Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of MCT homologues.
• the most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
• Recursive ensemble mutagenesis (REM) a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify MCT homologues (Arkin and Yourvan (1992) PNAS £9:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
• REM Recursive ensemble mutagenesis
• cell based assays can be exploited to analyze a variegated MCT library, using methods well known in the art.
• nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of C. glutamicum and related organisms; mapping of genomes of organisms related to C. glutamicum; identification and localization of C. glutamicum sequences of interest; evolutionary studies; determination of MCT protein regions required for function; modulation of an MCT protein activity; modulation of the metabolism of one or more cell membrane components; modulation of the transmembrane transport of one or more compounds; and modulation of cellular production of a desired compound, such as a fine chemical.
• the MCT nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof. Also, they may be used to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms.
• the invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present.
• Corynebacterium glutamicum itself is nonpathogenic, it is related to pathogenic species, such as Corynebacterium diphtheriae.
• Corynebacterium diphtheriae is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology.
• a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body.
• Degenerative changes brought about by the inhibition of protein synthesis in these tissues which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease.
• Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.
• the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject.
• This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth as odd-numbered or even-numbered SEQ ID NOs, respectively, in the Sequence Listing) in a subject, thereby detecting the presence or activity of
• Corynebacterium diphtheriae in the subject C. glutamicum and C. diphtheriae are related bacteria, and many of the nucleic acid and protein molecules in C. glutamicum are homologous to C. diphtheriae nucleic acid and protein molecules, and can therefore be used to detect C. diphtheriae in a subject.
• the nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of C. glutamicum proteins. For example, to identify the region of the genome to which a particular C. glutamicum DNA-binding protein binds, the C.
• glutamicum genome could be digested, and the fragments incubated with the DNA-binding protein.
• Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of C. glutamicum, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds.
• the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as Brevibacterium lactofermentum.
• the MCT nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies.
• the metabolic and transport processes in which the molecules of the invention participate are utilized by a wide variety of prokaryotic and eukaryotic cells; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.
• Manipulation of the MCT nucleic acid molecules of the invention may result in the production of MCT proteins having functional differences from the wild-type MCT proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.
• the invention provides methods for screening molecules which modulate the activity of an MCT protein, either by interacting with the protein itself or a substrate or binding partner of the MCT protein, or by modulating the transcription or translation of an MCT nucleic acid molecule of the invention.
• a microorganism expressing one or more MCT proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the MCT protein is assessed.
• fatty acids and lipids are themselves desirable fine chemicals, so by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from C. glutamicum.
• the engineering of one or more MCT genes of the invention may also result in
• MCT proteins having altered activities which indirectly impact the production of one or more desired fine chemicals from C .glutamicum For example, the normal biochemical processes of metabolism result in the production of a variety of waste products (e.g., hydrogen peroxide and other reactive oxygen species) which may actively interfere with these same metabolic processes (for example, peroxynitrite is known to nitrate tyrosine side chains, thereby inactivating some enzymes having tyrosine in the active site (Groves, J.T. (1999) Curr. Opin. Chem. Biol. 3(2): 226-235). While these waste products are typically excreted, the C.
• waste products e.g., hydrogen peroxide and other reactive oxygen species
• glutamicum strains utilized for large-scale fermentative production are optimized for the ove ⁇ roduction of one or more fine chemicals, and thus may produce more waste products than is typical for a wild-type C. glutamicum.
• By optimizing the activity of one or more MCT proteins of the invention which are involved in the export of waste molecules it may be possible to improve the viability of the cell and to maintain efficient metabolic activity.
• the presence of high intracellular levels of the desired fine chemical may actually be toxic to the cell, so by increasing the ability of the cell to secrete these compounds, one may improve the viability of the cell.
• the MCT proteins of the invention may be manipulated such that the relative amounts of various lipid and fatty acid molecules produced are altered.
• lipid composition of the membrane of the cell may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, which, as previously explicated, may modify the export of waste products or the produced fine chemical or the import of necessary nutrients. Such membrane fluidity changes may also profoundly affect the integrity of the cell; cells with relatively weaker membranes are more vulnerable in the large-scale fermentor environment to mechanical stresses which may damage or kill the cell.
• the nucleic acid and protein molecules of the invention may be utilized to generate C. glutamicum or related strains of bacteria expressing mutated MCT nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved.
• This desired compound may be any natural product of C. glutamicum, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of C. glutamicum, but which are produced by a C. glutamicum strain of the invention.
• NRRL ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA
• NCIMB National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK
• NT (GAP) Deposit rxa00051 1527 GBJHTG3 AC009685 210031 AC009685 Homo sapiens chromosome 15 clone 91_E_13 map 15, *** SEQUENCING IN Homo sapiens 34,247 29-Sep-
• GB_BA1 ECOUW93 338534 U14003 Escherichia coli K-12 chromosomal region from 92 8 to 00 1 minutes Escherichia coli 38,642 17-Apr- rxa00092 789 GB_BA1 SCH35 45396 AL078610 Streptomyces coehcolor cosmid H35 Streptomyces coehcolor 49,934 4-Jun-9
• GB_PL2 T24 8 68251 AF077409 Arabidopsis thahana BAC T24M8 Arabidopsis thaliana 37,150 3-Aug-9
• GB_BA1 MTCY270 37586 Z95388 Mycobacterium tuberculosis H37Rv complete genome, segment 96/162 Mycobacterium 42,874 10-Feb- tuberculosis rxa00113 5745
• IMAGE 843278 5' mRNA sequence rxa00243 1140 GB_PR2 CNS01 DS5 101584 AL121655 BAC sequence from the SPG4 candidate region at 2p21 -2p22, complete Homo sapiens 37,001 29-Sep- GB_HTG3 AC011408 79332 AC011408 Homo sapiens clone CIT978SKB_65D22, *** SEQUENCING IN PROGRESS *** , Homo sapiens 38,040 06-OCT-
• PdxJ pdxJ
• acyl earner protein synthase AcpS acpS genes
• GB_GSS8 AQ012142 501 AQ012142 8750H1A037010398 Cosmid library of chromosome II Rhodobacter sphaeroides Rhodobacter 54,800 4-Jun-98 genomic clone 8750H1A037010398, genomic survey sequence sphaeroides
• G B_HTG2 AC005081 180096 AC005081 Homo sapiens clone RG270D13, * ** SEQUENCING IN PROGRESS *** , 18 Homo sapiens 45,786 12-Jun-9 unordered pieces rxa00410 789 GB_BA1 ATPLOCC 8870 Z30328 A tumefaciens Ti plasmid pTiAch ⁇ genes for OccR, OccQ, OccM, OccP, OccT, Agrobacte ⁇ um 46,490 10-OCT-
• Plasmid pT ⁇ A6 (from Agribacte ⁇ um tumefaciens) pe ⁇ plasmic-type octopine Plasmid pT ⁇ A6 46,490 24-Apr-9 permease (occR, occQ, occM, occP, and occJ) and lysR-type regulatory protein
• GB_GSS14 AQ526586 434 AQ526586 HS_5198_B1_B03_SP6E RPCI-11 Human Male BAC Library
• NCI_CGAP_Thy1 Homo sapiens cDNA clone IMAGE 1133888 Homo sapiens 41 ,791 09-DEC- similar to gb M11353 HISTONE H3 3 (HUMAN),, mRNA sequence
• Rat PC-12 cells untreated Rattus sp cDNA clone RPCCK07 similar Rattus sp 39,267 2-Apr-98 to NADH-ubiquinone oxidoreductase complex I 23 kDa precursor (iron-sulfur protein), mRNA sequence
• Table 4 (continued) rxa00570 852 GB_GSS12 AQ422451 AQ422451 RPCI-11-185C3 TV RPCI-11 Homo sapiens genomic clone RPCI-11-185C3, Homo sapiens 38,767 23-MAR- genomic survey sequence GB_EST28 AI504741 AI504741 vl16c01 x1 Stratagene mouse Tcell 937311 Mus musculus cDNA clone Mus musculus 37,900 11-MAR-
• IMAGE 972384 3' similar to gb Z14044 M musculus mRNA for valosin-containmg protein (MOUSE),, mRNA sequence
• GB_PR3 AC005338 34541 AC005338 Homo sapiens chromosome 19, cosmid R31646, complete sequence Homo sapiens 36,911 30-Jul-9 rxa00590 1288 GB_HTG6 AC010932 203273 AC010932 Homo sapiens chromosome 15 clone RP11 -296E22 map 15, *** SEQUENCING Homo sapiens 37,242 30-Nov-
• GB_PR4 AF135802 4965 AF135802 Homo sapiens thyroid hormone receptor-associated protein complex component Homo sapiens 36,310 9-Apr-99
• GB_PR4 AF104256 4365 AF 104256 Homo sapiens transcriptional co-activator CRSP150 (CRSP150) mRNA
• Homo sapiens 36,617 4-Feb-9 complete eds rxa00596 576 GB_PR3 AC004659 129577 AC004659 Homo sapiens chromosome 19, CIT-HSP-87m17 BAC clone, complete Homo sapiens 34,321 02-MAY-
• GB_PR1 HUMCBP2 2047 D83174 Human mRNA for collagen binding protein 2, complete eds Homo sapiens 40,404 6-Feb-9 rxa00607 504 GB_BA1 MTV010 3400 AL021186 Mycobacterium tuberculosis H37Rv complete genome, segment 119/162 Mycobacterium 40,862 23-Jun-9 tuberculosis
• GB_BA1 MTV010 3400 AL021186 Mycobacterium tuberculosis H37Rv complete genome, segment 119/162 Mycobacterium 38,833 23-Jun-9 tuberculosis rxa00623 1461 GB BA1 MTCY428 26914 Z81451 Mycobacterium tuberculosis H37Rv complete genome, segment 107/162 Mycobacterium 60,552 17-Jun- tuberculosis
• PROGRESS *** 27 unordered pieces rxa00733 1008 GB EST30 AU054038 245 AU054038 AU054038 Dictyostehum discoideum SL (H Urushihara) Dictyostehum Dictyostehum discoideum 43,265 28-Apr-9 discoideum cDNA clone SLK472, mRNA sequence
• GB_PR4 AC007625 174701 AC007625 Genomic sequence of Homo sapiens clone 2314F2 from chromosome 18, Homo sapiens 38,014 30-Jun-9 complete sequence
• PROGRESS ***, 49 unordered pieces rxa00821 966 GBJHTG1 HS32B1 271488 AL023693 Homo sapiens chromosome 6 clone RP1-32B1 , *** SEQUENCING IN Homo sapiens 36,565 23-NOV-9
• GBJN1 CEF02D8 31624 Z78411 Caenorhabditis elegans cosmid F02D8, complete sequence Caenorhabditis elegans 38,163 23-NOV-9 rxa00847 1572 GB_OV XELRDS38A 1209 L79915 Xenopus laevis rds/pe ⁇ pherin (rds38) mRNA, complete eds Xenopus laevis 36,044 30-Jul-97
• GB_HTG4 AC007920 234529 AC007920 Homo sapiens chromosome 3q27 clone RPCI11-208N14, ** * SEQUENCING IN Homo sapiens 33,742 21-OCT-
• GB_HTG4 AC007920 234529 AC007920 Homo sapiens chromosome 3q27 clone RPCI1 1-208N14, *** SEQUENCING IN Homo sapiens 33,742 21-OCT-
• PROGRESS ***, 51 unordered pieces rxa00851 732 GB_HTG2 AC004064 185000 AC004064 Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS " * , 10 Homo sapiens 39,833 9-Jul-98 unordered pieces
• GB_BA2 MSGKATG 1745 L 14268 Mycobacterium tuberculosis ethyl methane sulphonate resistance protein (katG) Mycobacterium 42,517 26-Aug-9 gene, 3'end tuberculosis rxa00962 689 GB_HTG6 AC010998 144338 AC010998 Homo sapiens clone RP11-95116, *** SEQUENCING IN PROGRESS " * , 17 Homo sapiens 39,497 08-DEC- unordered pieces
• GB_HTG6 AC010998 144338 AC010998 Homo sapiens clone RP11-95I16, *** SEQUENCING IN PROGRESS *** , 17 Homo sapiens 38,226 08-DEC- unordered pieces rxa01060 1047 GB_BA1 ECTTN7 2280 AJ001816 Escherichia coli left end of transposon Tn7 including type 2 integron Escherichia coli 38,822 4-NOV-9
• GBJN2 AF1 6377 8220 AF176377 Caenorhabditis briggsae CES-1 (ces-1 ) gene, complete eds, and CPN-1 (cpn-1 ) Caenorhabditis briggsae 39,921 09-DEC- gene, partial eds
• GB_GSS10 AQ 196728 429 AQ 196728 CIT-HSP-2381 F4 TR CIT-HSP Homo sapiens genomic clone 2381 F4, genomic Homo sapiens 39,019 16-Sep- survey sequence rxa01067 852 GB_BA1 U00016 42931 U00016 Mycobacterium leprae cosmid B1937 Mycobacterium leprae 58,303 01 -MAR-
• GB_BA1 AB014757 6057 AB014757 Pseudomonas sp 61-3 genes for PhbR, acetoacetyl-CoA reductase, beta- Pseudomonas sp 61-3 50,573 26-DEC-1 ketothiolase and PHB synthase, complete eds
• GB_PR4 AC006054 143738 AC006054 Homo sapiens Xq28 BAC RPCI11-382P7 (Roswell Park Cancer Institute Human Homo sapiens 36,053 1-Apr-99
• GB_PL2 ATT6K21 99643 AL021889 Arabidopsis thahana DNA chromosome 4, BAC clone T6K21 (ESSA project) Arabidopsis thahana 35,273 16-Aug-9 rxa01212 1047 GB_BA2 SCD25 41622 AL118514 Streptomyces coehcolor cosmid D25 Streptomyces coehcolor 39,654 21-Sep-9
• IMAGE 309573 3' mRNA sequence GB EST16 AA554268 400 AA554268 nk36c09 s1 NCI_CGAP_GC2
• Homo sapiens cDNA clone IMAGE 1015600 3' Homo sapiens 36,111 8-Sep-9 similar to gb X01677 GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE,
• GBJN1 BBU44918 2791 U44918 Babesia bovis ATP-binding protein (babe) mRNA, complete eds Babesia bovis 39,228 9-Aug-9 rxa01260 1305 GB_BA1 CGLPD 1800 Y16642 Corynebacterium glutamicum Ipd gene, complete CDS Corynebacterium 99,923 1-Feb-9 glutamicum
• GB_PR3 AC005618 176714 AC005618 Homo sapiens chromosome 5, BAC clone 249h5 (LBNL H149), complete Homo sapiens 36,270 5-Sep-9 sequence rxa01261 294 GB_BA1 CGLPD 1800 Y16642 Corynebacterium glutamicum Ipd gene, complete CDS Corynebacterium 100,000 1-Feb-9 glutamicum
• GB STS AU027820 238 AU027820 Rattus norvegicus, OTSUKA clone, OT78 02/918b07, microsatelhte sequence, Rattus norvegicus 34,874 02-MAR- sequence tagged site
• GBJHTG3 AC006445 174547 AC006445 Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, 7 Homo sapiens 34,812 15-Sep-9 unordered pieces rxa01292 1308 GB_BA1 BSUB0017 217420 Z99120 Bacillus subtilis complete genome (section 17 of 21 ) from 3197001 to 3414420 Bacillus subtilis 37,802 26-Nov-9
• PROGRESS *** 31 unordered pieces rxa01382 1192 GBJHTG4 AC009892 138122 AC009892 Homo sapiens chromosome 19 clone CIT978SKB_83J4, * SEQUENCING IN Homo sapiens 40,154 31-OCT-
• GB_PR3 AC002416 128915 AC002416 Human Chromosome X complete sequence Homo sapiens 37,521 29-Jan-9 rxa01399 1142 GB_EST9 AA096601 524 AA096601 mo03b09 r1 Stratagene mouse lung 937302 Mus musculus cDNA clone Mus musculus 40,525 15-Feb-9
• GB_OV GGU20766 1645 U20766 Gallus gallus vacuolar H+-ATPase B subunit gene, complete eds Gallus gallus 38,244 07-DEC- rxa01420 1065 GBJHTG2 AC005690 193424 AC005690 Homo sapiens chromosome 4, * ** SEQUENCING IN PROGRESS *** , 7 Homo sapiens 37,464 11-Apr-9 unordered pieces
• GB_PR4 AF191071 88481 AF191071 Homo sapiens chromosome 8 clone BAC 388D06, complete sequence Homo sapiens 35,612 11-OCT- rxa01644 1401 GB_BA1 MSGB577CO 37770 L01263 M leprae genomic dna sequence, cosmid b577 Mycobacterium leprae 55,604 14-Jun-9
• GB_HTG6 AC011037 167849 AC011037 Homo sapiens clone RP11 -7F18, WORKING DRAFT SEQUENCE, 19 Homo sapiens 35,642 30-Nov-9 unordered pieces rxa01737 1182 GB_BA1 SCGD3 33779 AL096822 Streptomyces coehcolor cosmid GD3 Streptomyces coehcolor 38,054 8-Jul-99
• GB_GSS13 AQ489971 252 AQ489971 RPCI-11 -247N23 TV RPCI-11 Homo sapiens genomic clone RPCI-11 -247N23, Homo sapiens 36,111 24-Apr-9 genomic survey sequence rxa01823 900 GB_BA1 SCI51 40745 AL109848 Streptomyces coehcolor cosmid 151 Streptomyces coehcolor 35,779 16-Aug-9
• GB_BA1 BSUB0018 209510 Z99121 Bacillus subtilis complete genome (section 18 of 21) from 3399551 to 3609060 Bacillus subtilis 36,999 26-Nov-9 rxa01853 675
• GB_HTG3 AC010189 265962 AC010189 Homo sapiens clone RPCI1 1-296K13, *** SEQUENCING IN PROGRESS *** , 80 Homo sapiens 39,006 16-Sep-9 unordered pieces rxa01881 558 GB_HTG4 AC011117 148447 AC011117 Homo sapiens chromosome 4 clone 173_C_09 map 4, *** SEQUENCING IN Homo sapiens 39,130 14-OCT- PROGRESS *** , 10 ordered pieces
• PROGRESS *** in unordered pieces rxa01946 1298 GB_BA1 MTV007 32806 AL021184 Mycobacterium tuberculosis H37Rv complete genome, segment 64/162 Mycobacterium 65,560 17-Jun-98 tuberculosis GB_BA1 SC5F2A 40105 AL049587 Streptomyces coehcolor cosmid 5F2A Streptomyces coehcolor 50,648 24-MAY-1
• GB_BA1 SCARD1GN 2321 X84374 S capreolus ardl gene Streptomyces capreolus 44,973 23-Aug-9 rxa01980 756
• GB_PL2 AC008262 99698 AC008262
• GB_PL1 AB013388 73428 AB013388 Arabidopsis thahana genomic DNA, chromosome 5, TAC clone K19E1 , Arabidopsis thahana 39,973 20-Nov-9 complete sequence rxa01983 630 GBJHTG4 AC006467 175695 AC006467 Drosophila melanogaster chromosome 2 clone BACR03L08 (D532) RPCI-98 Drosophila melanogaster 36,672 27-OCT-1
• GB_PR4 AC006464 99908 AC006464 Homo sapiens BAC clone NH0436C12 from 2, complete sequence Homo sapiens 35,445 22-OCT- GB_PR4 AC006464 99908 AC006464 Homo sapiens BAC clone NH0436C12 from 2, complete sequence Homo sapiens 35,968 22-OCT- rxa02073 1653 GB_BA1 CGGDHA 2037 X72855 C glutamicum GDHA gene Corynebacterium 39,655 24-MAY- glutamicum
• IMAGE 450035 3' similar to contains LTR5 t3 LTR5 repetitive element ,, mRNA sequence
• GB_HTG6 AC009769 122911 AC009769 Homo sapiens chromosome 8 clone RP11-202112 map 8, LOW-PASS Homo sapiens 35,473 07-DEC-
• IMAGE 344258 5' similar to contains LTR5 b2 LTR5 repetitive element,, mRNA sequence rxa02099 373 GB_BA1 CAJ10319 5368 AJ010319 Corynebacterium glutamicum amtP, glnB, glnD genes and partial ftsY and srp Corynebacterium 100,000 14-MAY- genes glutamicum
• PROGRESS *** 35 unordered pieces rxa02115 1197 GBJHTG5 AC010126 175986 AC010126 Homo sapiens clone GS502B02, *** SEQUENCING IN PROGRESS *** , 3 Homo sapiens 36,717 13-NOV- unordered pieces
• GB_PR1 HUMHM145 2214 D 10925 Human mRNA for HM145 Homo sapiens 39,171 3-Feb-9 rxa02128 1818 GB_BA1 MTCY190 34150 Z70283 Mycobacterium tuberculosis H37Rv complete genome, segment 98/162 Mycobacterium 38,682 17-Jun- tuberculosis
• GB_GSS10 AQ161109 738 AQ161109 nbxb0006D03r
• GB_PR4 AC005042 192218 AC005042 Homo sapiens clone NH0552E01 , complete sequence Homo sapiens 36,901 14-Jan-9 rxa02171 1776 GB_BA2 AF010496 189370 AF010496 Rhodobacter capsulatus strain SB1003, partial genome Rhodobacter capsulatus 53,714 12-MAY-
• GB_BA2 AE000104 10146 AE000104 Rhizobium sp NGR234 plasmid pNGR234a section 41 of 46 of the complete Rhizobium sp NGR234 38,487 12-DEC- plasmid sequence rxa02224 1920
• PROGRESS *** 2 ordered pieces rxa02225 905 GB_BA2 MPAE000058 28530 AE000058 Mycoplasma pneumoniae section 58 of 63 of the complete genome Mycoplasma 35,498 18-NOV- pneumoniae
• GB_HTG3 AC009293 162944 AC009293 Homo sapiens chromosome 18 clone 53_l_06 map 18, * ** SEQUENCING IN Homo sapiens 37,006 13-Aug- PROGRESS *** , 15 unordered pieces rxa02309 1173 GB_BA1 MTY25D10 40838 Z95558 Mycobacterium tuberculosis H37Rv complete genome, segment 28/162 Mycobacterium 52,344 17-Jun-9 tuberculosis
• GBJHTG2 AC007163 186618 AC007163 Homo sapiens clone NH0091M05, *** SEQUENCING IN PROGRESS *** , 1 Homo sapiens 37,263 23-Apr-9 unordered pieces rxa02310 1386 GB_BA1 MTY25D10 40838 Z95558 Mycobacterium tuberculosis H37Rv complete genome, segment 28/162 Mycobacterium 36,861 17-Jun-9 tuberculosis
• GB_PR3 AC005224 166687 AC005224 Homo sapiens chromosome 17, clone hRPK 214_0_1 , complete sequence Homo sapiens 33,427 14-Aug-98 rxa02426 1656 GB_PAT A06664 1350 A06664 B stearothermophilus let gene Bacillus 39,936 29-Jul-93 stearothermophilus
• GB_BA2 AF 119621 15986 AF119621 Pseudomonas abietaniphila BKME-9 Ditl (ditl), dioxygenase DitA oxygenase Pseudomonas 43,611 28-Apr-99 component small subunit (d ⁇ tA2), dioxygenase DitA oxygenase component large abietaniphila subunit (d ⁇ tA1 ), DitH (ditH), DitG (ditG), DitF (ditF), DitR (ditR), DitE (ditE), DitD
• PROTEIN PLZF mRNA sequence rxa02512 1086 GB BA1 MTCY1A10 25949 Z95387 Mycobacterium tuberculosis H37Rv complete genome, segment 117/162 Mycobacterium 37,407 17-Jun-98 tuberculosis
• GBJDV GGU43396 2738 U43396 Gallus gallus tropomyosin receptor kinase A (ctrkA) mRNA, complete eds Gallus gallus 38,789 18-Jan-96 rxa02527 1452 GB BA2 AF008220 220060 AF008220 Bacillus subtilis rrnB-dnaB genomic region Bacillus subtilis 37,395 4-Feb-98
• GB_BA2 AF008220 220060 AF008220 Bacillus subtilis rrnB-dnaB genomic region Bacillus subtilis 36,218 4-Feb-98
• GB_PL1 AB006530 7344 AB006530 Citrullus lanatus Sat gene for serine acetyltransferase, complete eds and 5'- Citrullus lanatus 34,646 20-Aug-97 flankmg region rxa02566 1332 GB_EST32 AI727189 619 AI727189 BNLGH ⁇ 7498 Six-day Cotton fiber Gossypium hirsutum cDNA 5' similar to Gossypium hirsutum 35,099 11-Jun-99
• GB_PL2 SPAC13G6 33481 Z54308 S pombe chromosome I cosmid c13G6 Sch izosaccha romyces 35,774 18-OCT-1999 pombe rxa02571 1152
• GB_BA1 CGU43535 2531 U43535 Corynebacterium glutamicum multidrug resistance protein (cmr) gene, complete Corynebacterium 41 ,872 9-Apr-97 eds glutamicum

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Plant Pathology (AREA)
• Gastroenterology & Hepatology (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Peptides Or Proteins (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (2)

Applications Claiming Priority (71)

Related Child Applications (1)

Publications (1)

Family

ID=27586932

Family Applications (1)

Country Status (10)

Families Citing this family (29)

Family Cites Families (5)

• 2000
  • 2000-06-23 KR KR1020017016590A patent/KR100834989B1/ko not_active IP Right Cessation
  • 2000-06-23 TR TR2001/03708T patent/TR200103708T2/xx unknown
  • 2000-06-23 KR KR1020077015871A patent/KR20070087032A/ko not_active Application Discontinuation
  • 2000-06-23 ES ES00939001T patent/ES2177476T1/es active Pending
  • 2000-06-23 KR KR1020067022650A patent/KR100878332B1/ko active IP Right Grant
  • 2000-06-23 TR TR2006/07442T patent/TR200607442T2/xx unknown
  • 2000-06-23 JP JP2001506799A patent/JP2004513603A/ja active Pending
  • 2000-06-23 EP EP00939001A patent/EP1255839A2/en not_active Ceased
  • 2000-06-23 SK SK1891-2001A patent/SK18912001A3/sk not_active Application Discontinuation
  • 2000-06-23 CA CA002380863A patent/CA2380863A1/en not_active Abandoned
  • 2000-06-23 TR TR2006/07441T patent/TR200607441T2/xx unknown
  • 2000-06-23 CZ CZ20014660A patent/CZ20014660A3/cs unknown
  • 2000-06-23 TR TR2006/07443T patent/TR200607443T2/xx unknown
  • 2000-06-23 WO PCT/IB2000/000926 patent/WO2001000805A2/en active Application Filing
  • 2000-06-23 MX MXPA01012845A patent/MXPA01012845A/es not_active Application Discontinuation
• 2006
  • 2006-05-11 JP JP2006132306A patent/JP2006271389A/ja not_active Withdrawn

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events